Resmed Mini L (RMDKOA) Quote

$SOPA big week coming

Once again: $4 billion is the total value of the project (all phases) including the land! $250 million was the original estimate of the revenue XERI would generate from the sale of NexBoard to NNC.

Dividends to epaz shareholders is a way to reward shareholders for the Bitcoin Tokens sales as it roles out...using solar.

Most epaz shareholders are in the USA where there not offered.

$VGLS stock price in 2024 now indicates an average price target of $0.00039 with a high forecast of $0.000754 and a low forecast of $0.000027. The average prediction reflects an increase of +290.24% from the last recorded price of $0.0001.
https://stockscan.io/stocks/VGLS

AKAN .1358

Oh my!!!

FYI: Not in $RILY since Friday - but something strange in the option market. I'll try and have it all out later, but there is over $30 mil in Notional Value on the May 17th calls side, with a large amount of deep-in-the-money strikes...

That is just one expiry... maybe nothing or mayb

It’s the same as before except no stock price posted.

Researchers have price forecast PLANTX this year.
Currently it`s between 5X and about 20X... depending on source.
Do your own due diligence.

https://vegainvestors.com/news/analysts-repor...s-vega-cn/

CAD SECURITY EXCHANGE PRICE FRANKFURT: WNT1 | OTCQB: PL

Everyone holding this has been rugged and you still won’t accept it! Keep dreaming…keep dreaming! And when you see all those zeros after the decimal point and not before it, wake up and smell the coffee!

Attorney letter posted yesterday.

https://www.otcmarkets.com/otcapi/company/financial-report/399391/content

IBRX!!!

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-immunitybios-bladder-cancer-therapy-2024-04-22/

Roku price target lowered to $80 from $110 at Susquehanna
Susquehanna analyst Shyam Patil lowered the firm's price target on Roku to $80 from $110 and keeps a Positive rating on the shares. The firm said they reported a solid 1Q with revenue and profitability above expectations. While 2Q head

Another key agreement with the vietnamese government. Well done Kim!!!!

$$$KBLB$$$$

time does fly when you are financially free :)

IBRX IBRX IBRX!!!! FDA APPROVAL BLADDER CANCER SQUUUUUUEZE!!!

SoFi Technologies sees Q2 revenue $555M-$565M, consensus $580.73M
The company said, "For the second quarter of 2024, management expects to deliver adjusted net revenues of $555 to $565 million, adjusted EBITDA of $115 to $125 million and Net Income of $5 to $10 million."

SoFi Technologies reports Q1 EPS 2c, consensus 1c
Reports Q1 revenue $645M, consensus $556M. Reports Q1 tangible book value per share $3.92. Anthony Noto, CEO of SoFi Technologies, Inc. commented: "Our first quarter was an exceptionally strong start to 2024, demonstrating significant momentum

Researchers have a price estimation on PLANTX this year. Currently it`s between 5X and about 20X...
do your due diligence, I`m invested in the company.

https://vegainvestors.com/news/analysts-repor...s-vega-cn/

CAD SECURITY EXCHANGE PRICE FRANKFURT: WNT1 | OTCQB

HUH?? I can't be with you and agree with your posts at the same time?! Believe me I am not a follower, but that doesn't prevent me from indicating my agreement or disagreement with your posts or portions thereof.
Your use of the word semantics for instance is non sensical.

$SMCI 14.7%
$AAPL 4.6%
$COIN 12.9%
$AMZN 7.6%
$SQ 11.7%
$DKNG 10.8%
$AMD 8.6%
$NVO 6.1%
$MCD 3.0%
$PYPL 9.1%
$LLY 5.2%
$SBUX 6.6%
$QCOM 7.9%
$CVNA 17.9%
$ETSY 11.3%
$FSLY 18.1%
$FSLR 9.0%

Yes, very good. Second straight profitable quarter. Blow the lid off this thing!

Goooood ROBUST $RNVA morning!!

Still here as well - just watching and waiting for the series of pops. This is as real as it gets with these types of stocks. I have been here since 2014 and have enjoyed the progression over the years and sooooo happy to be here for their giant leap. Nice to see you are still here Catfigh and Hunte

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
Apr 29, 2024

WATERTOWN, Mass.--(BUSINESS WIRE)--Apr. 29, 2024-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-st